{
  "metadata": {
    "graph_path": "./logic_graph.png",
    "num_solutions": 4,
    "family_stats": {
      "1": {
        "core": 1,
        "branch": 0
      },
      "2": {
        "core": 1,
        "branch": 1
      },
      "3": {
        "core": 1,
        "branch": 0
      }
    }
  },
  "knowledge_base": {
    "rules": [
      {
        "id": "Rule1",
        "formal": "(A11 → G)",
        "prover9_expression": "(effective(drug_treatment) -> profitable(pharmaceutical_company))",
        "natural": "Under the condition that the drug treatment is effective, the pharmaceutical company is profitable."
      },
      {
        "id": "Rule2",
        "formal": "(A12 → (A10 → A11))",
        "prover9_expression": "(robust(statistical_analysis) -> (positive(clinical_results) -> effective(drug_treatment)))",
        "natural": "Whenever the statistical analysis is robust, then if the clinical results are positive, the drug treatment is effective."
      },
      {
        "id": "Rule3",
        "formal": "(A12 ∨ A13)",
        "prover9_expression": "(robust(statistical_analysis) | reliable(patient_data))",
        "natural": "Either the statistical analysis is robust or the patient data is reliable."
      },
      {
        "id": "Rule4",
        "formal": "(A14 ∨ (A13 → (A10 → A11)))",
        "prover9_expression": "(biased(sample_selection) | (reliable(patient_data) -> (positive(clinical_results) -> effective(drug_treatment))))",
        "natural": "Either the sample selection is biased, or if the patient data is reliable, then positive clinical results lead to effective drug treatment."
      },
      {
        "id": "Rule5",
        "formal": "(A17 → (A16 → A15))",
        "prover9_expression": "(completed(phase_3_trial) -> (identified(safety_issues) -> dangerous(side_effects)))",
        "natural": "In the event that the phase 3 trial is completed, then if safety issues are identified, the side effects are dangerous."
      },
      {
        "id": "Rule6",
        "formal": "(A18 → (A16 → A15))",
        "prover9_expression": "(accelerated(fda_review) -> (identified(safety_issues) -> dangerous(side_effects)))",
        "natural": "Whenever the FDA review is accelerated, then if safety issues are identified, the side effects are dangerous."
      },
      {
        "id": "Rule7",
        "formal": "(A20 → (A17 ∨ A18))",
        "prover9_expression": "(increased(market_share) -> (completed(phase_3_trial) | accelerated(fda_review)))",
        "natural": "Whenever the market share increases, either the phase 3 trial was completed or the FDA review was accelerated."
      },
      {
        "id": "Rule8",
        "formal": "(A21 → A20)",
        "prover9_expression": "(positive(public_perception) -> increased(market_share))",
        "natural": "If the public perception is positive, then the market share increases."
      },
      {
        "id": "Rule9",
        "formal": "(A22 ∨ (A19 → A21))",
        "prover9_expression": "(negative(media_coverage) | (launched(marketing_campaign) -> positive(public_perception)))",
        "natural": "Either the media coverage is negative, or if the marketing campaign is launched, the public perception is positive."
      },
      {
        "id": "Rule10",
        "formal": "(A23 → (A13 → (A10 → A11)))",
        "prover9_expression": "(thorough(data_validation) -> (reliable(patient_data) -> (positive(clinical_results) -> effective(drug_treatment))))",
        "natural": "Assuming that the data validation is thorough, then if the patient data is reliable, then positive clinical results lead to effective drug treatment."
      },
      {
        "id": "Rule11",
        "formal": "(A24 → (A13 → (A10 → A11)))",
        "prover9_expression": "(independent(expert_review) -> (reliable(patient_data) -> (positive(clinical_results) -> effective(drug_treatment))))",
        "natural": "Under the condition that the expert review is independent, then if the patient data is reliable, then positive clinical results imply effective drug treatment."
      },
      {
        "id": "Rule12",
        "formal": "(A25 ∨ A26)",
        "prover9_expression": "(adequate(research_budget) | private(industry_funding))",
        "natural": "Either the research budget is adequate or the industry funding is private."
      },
      {
        "id": "Rule13",
        "formal": "(A26 → A24)",
        "prover9_expression": "(private(industry_funding) -> independent(expert_review))",
        "natural": "Provided that the industry funding is private, the expert review is independent."
      },
      {
        "id": "Rule14",
        "formal": "(A28 → ¬A27)",
        "prover9_expression": "(transparent(research_methodology) -> -fraudulent(research_data))",
        "natural": "If the research methodology is transparent, then it is not the case that the research data is fraudulent."
      },
      {
        "id": "Rule15",
        "formal": "(A3 → A2)",
        "prover9_expression": "(published(journal_article) -> approved(drug))",
        "natural": "Whenever the journal article is published, the drug is approved."
      },
      {
        "id": "Rule16",
        "formal": "(A31 → ¬A30)",
        "prover9_expression": "(credible(peer_review) -> -manipulated(statistical_results))",
        "natural": "In the event that the peer review is credible, it is not the case that the statistical results were manipulated."
      },
      {
        "id": "Rule17",
        "formal": "(A4 → ¬A1)",
        "prover9_expression": "(rejected(journal_article) -> -discontinued(clinical_trial))",
        "natural": "If the journal article is rejected, then it is not the case that the clinical trial was discontinued."
      },
      {
        "id": "Rule18",
        "formal": "(A5 → ¬A6)",
        "prover9_expression": "(conflicts_with(funding_source, ethics_committee) -> -compliant(funding_source, regulations))",
        "natural": "Assuming that the funding source conflicts with the ethics committee, it does not hold that the funding source is compliant with regulations."
      },
      {
        "id": "Rule19",
        "formal": "(A5 ∨ (A3 ∨ A4))",
        "prover9_expression": "(conflicts_with(funding_source, ethics_committee) | (published(journal_article) | rejected(journal_article)))",
        "natural": "Either the funding source conflicts with the ethics committee, or either the journal article is published or the journal article is rejected."
      },
      {
        "id": "Rule20",
        "formal": "(A8 ∨ ¬A7)",
        "prover9_expression": "(proper(patient_screening) | -valid(informed_consent))",
        "natural": "Either the patient screening is proper or the informed consent is not valid."
      },
      {
        "id": "Rule21",
        "formal": "(A9 → G)",
        "prover9_expression": "(successful(pilot_study) -> profitable(pharmaceutical_company))",
        "natural": "If the pilot study is successful, then the pharmaceutical company is profitable."
      },
      {
        "id": "Rule22",
        "formal": "(A9 ∨ A10)",
        "prover9_expression": "(successful(pilot_study) | positive(clinical_results))",
        "natural": "Either the pilot study is successful or the clinical results are positive."
      },
      {
        "id": "Rule23",
        "formal": "(¬(A25 → A23) → A27)",
        "prover9_expression": "(-(adequate(research_budget) -> thorough(data_validation)) -> fraudulent(research_data))",
        "natural": "If it is not the case that if the research budget is adequate then the data validation is thorough, then the research data is fraudulent."
      },
      {
        "id": "Rule24",
        "formal": "(¬(A5 → A6) → A7)",
        "prover9_expression": "(-(conflicts_with(funding_source, ethics_committee) -> compliant(funding_source, regulations)) -> valid(informed_consent))",
        "natural": "If it does not hold that if the funding source conflicts with the ethics committee then the funding source is compliant with regulations, then the informed consent is valid."
      },
      {
        "id": "Rule25",
        "formal": "(¬(¬A28 → A29) → A30)",
        "prover9_expression": "(-(-transparent(research_methodology) -> accessible(raw_data)) -> manipulated(statistical_results))",
        "natural": "If it is not the case that if the research methodology is not transparent then the raw data is accessible, then the statistical results were manipulated."
      },
      {
        "id": "Rule26",
        "formal": "(¬G → A1)",
        "prover9_expression": "(-profitable(pharmaceutical_company) -> discontinued(clinical_trial))",
        "natural": "In the event that the pharmaceutical company is not profitable, the clinical trial was discontinued."
      },
      {
        "id": "Rule27",
        "formal": "(¬G → A16)",
        "prover9_expression": "(-profitable(pharmaceutical_company) -> identified(safety_issues))",
        "natural": "Under the condition that the pharmaceutical company is not profitable, safety issues were identified."
      },
      {
        "id": "Rule28",
        "formal": "(¬G → ¬A15)",
        "prover9_expression": "(-profitable(pharmaceutical_company) -> -dangerous(side_effects))",
        "natural": "Whenever the pharmaceutical company is not profitable, it does not hold that the side effects are dangerous."
      }
    ],
    "facts": [
      {
        "id": "Fact1",
        "formal": "A19",
        "prover9_expression": "launched(marketing_campaign)",
        "natural": "The marketing campaign was launched."
      },
      {
        "id": "Fact2",
        "formal": "A31",
        "prover9_expression": "credible(peer_review)",
        "natural": "The peer review is credible."
      },
      {
        "id": "Fact3",
        "formal": "¬A14",
        "prover9_expression": "-biased(sample_selection)",
        "natural": "The sample selection is not biased."
      },
      {
        "id": "Fact4",
        "formal": "¬A2",
        "prover9_expression": "-approved(drug)",
        "natural": "The drug is not approved."
      },
      {
        "id": "Fact5",
        "formal": "¬A22",
        "prover9_expression": "-negative(media_coverage)",
        "natural": "The media coverage is not negative."
      },
      {
        "id": "Fact6",
        "formal": "¬A29",
        "prover9_expression": "-accessible(raw_data)",
        "natural": "The raw data is not accessible."
      },
      {
        "id": "Fact7",
        "formal": "¬A8",
        "prover9_expression": "-proper(patient_screening)",
        "natural": "The patient screening is not proper."
      }
    ]
  },
  "target": {
    "formal": "G",
    "prover9": "G",
    "prover9_expression": "profitable(pharmaceutical_company)",
    "natural": "The pharmaceutical company is profitable."
  },
  "solutions": [
    {
      "id": 1,
      "family_id": 1,
      "path_type": "core",
      "branch_from": null,
      "steps": [
        {
          "step_number": 1,
          "rule_applied": "DS",
          "premises_used": [
            "(A8 | -A7)",
            "-A8"
          ],
          "conclusion": "-A7",
          "natural": "The informed consent is not valid."
        },
        {
          "step_number": 2,
          "rule_applied": "MT",
          "premises_used": [
            "(-(A5 -> A6) -> A7)",
            "-A7"
          ],
          "conclusion": "(A5 -> A6)",
          "natural": "Under the condition that the funding source conflicts with the ethics committee, the funding source is compliant with regulations."
        },
        {
          "step_number": 3,
          "rule_applied": "RAA",
          "premises_used": [
            "(A5 -> A6)",
            "(A5 -> -A6)"
          ],
          "conclusion": "-A5",
          "natural": "The funding source does not conflict with the ethics committee."
        },
        {
          "step_number": 4,
          "rule_applied": "DS",
          "premises_used": [
            "(A5 | (A3 | A4))",
            "-A5"
          ],
          "conclusion": "(A3 | A4)",
          "natural": "Either the journal article is published or the journal article is rejected."
        },
        {
          "step_number": 5,
          "rule_applied": "CD",
          "premises_used": [
            "(A3 -> A2)",
            "(A4 -> -A1)",
            "(A3 | A4)"
          ],
          "conclusion": "(A2 | -A1)",
          "natural": "Either the drug is approved or it is not the case that the clinical trial was discontinued."
        },
        {
          "step_number": 6,
          "rule_applied": "DS",
          "premises_used": [
            "(A2 | -A1)",
            "-A2"
          ],
          "conclusion": "-A1",
          "natural": "It is not the case that the clinical trial was discontinued."
        },
        {
          "step_number": 7,
          "rule_applied": "MT",
          "premises_used": [
            "(-G -> A1)",
            "-A1"
          ],
          "conclusion": "G",
          "natural": "The pharmaceutical company is profitable."
        }
      ]
    },
    {
      "id": 2,
      "family_id": 2,
      "path_type": "core",
      "branch_from": null,
      "steps": [
        {
          "step_number": 1,
          "rule_applied": "DS",
          "premises_used": [
            "(A14 | (A13 -> (A10 -> A11)))",
            "-A14"
          ],
          "conclusion": "(A13 -> (A10 -> A11))",
          "natural": "Assuming that the patient data is reliable, then if the clinical results are positive, the drug treatment is effective."
        },
        {
          "step_number": 2,
          "rule_applied": "DE",
          "premises_used": [
            "(A12 | A13)",
            "(A12 -> (A10 -> A11))",
            "(A13 -> (A10 -> A11))"
          ],
          "conclusion": "(A10 -> A11)",
          "natural": "If the clinical results are positive, then the drug treatment is effective."
        },
        {
          "step_number": 3,
          "rule_applied": "HS",
          "premises_used": [
            "(A10 -> A11)",
            "(A11 -> G)"
          ],
          "conclusion": "(A10 -> G)",
          "natural": "Provided that the clinical results are positive, the pharmaceutical company becomes profitable."
        },
        {
          "step_number": 4,
          "rule_applied": "DE",
          "premises_used": [
            "(A9 | A10)",
            "(A9 -> G)",
            "(A10 -> G)"
          ],
          "conclusion": "G",
          "natural": "The pharmaceutical company is profitable."
        }
      ]
    },
    {
      "id": 3,
      "family_id": 3,
      "path_type": "core",
      "branch_from": null,
      "steps": [
        {
          "step_number": 1,
          "rule_applied": "DS",
          "premises_used": [
            "(A22 | (A19 -> A21))",
            "-A22"
          ],
          "conclusion": "(A19 -> A21)",
          "natural": "Provided that the marketing campaign is launched, the public perception is positive."
        },
        {
          "step_number": 2,
          "rule_applied": "HS",
          "premises_used": [
            "(A19 -> A21)",
            "(A21 -> A20)"
          ],
          "conclusion": "(A19 -> A20)",
          "natural": "If the marketing campaign is launched, then the market share increases."
        },
        {
          "step_number": 3,
          "rule_applied": "HS",
          "premises_used": [
            "(A19 -> A20)",
            "(A20 -> (A17 | A18))"
          ],
          "conclusion": "(A19 -> (A17 | A18))",
          "natural": "Under the condition that the marketing campaign is launched, either the phase 3 trial was completed or the FDA review was accelerated."
        },
        {
          "step_number": 4,
          "rule_applied": "MP",
          "premises_used": [
            "(A19 -> (A17 | A18))",
            "A19"
          ],
          "conclusion": "(A17 | A18)",
          "natural": "Either the phase 3 trial was completed or the FDA review was accelerated."
        },
        {
          "step_number": 5,
          "rule_applied": "DE",
          "premises_used": [
            "(A17 | A18)",
            "(A17 -> (A16 -> A15))",
            "(A18 -> (A16 -> A15))"
          ],
          "conclusion": "(A16 -> A15)",
          "natural": "If safety issues are identified, then the side effects are dangerous."
        },
        {
          "step_number": 6,
          "rule_applied": "HS",
          "premises_used": [
            "(-G -> A16)",
            "(A16 -> A15)"
          ],
          "conclusion": "(-G -> A15)",
          "natural": "Provided that the pharmaceutical company is not profitable, the side effects are dangerous."
        },
        {
          "step_number": 7,
          "rule_applied": "RAA",
          "premises_used": [
            "(-G -> A15)",
            "(-G -> -A15)"
          ],
          "conclusion": "G",
          "natural": "The pharmaceutical company is profitable."
        }
      ]
    },
    {
      "id": 4,
      "family_id": 2,
      "path_type": "branch",
      "branch_from": 0,
      "steps": [
        {
          "step_number": 1,
          "rule_applied": "MP",
          "premises_used": [
            "(A31 -> -A30)",
            "A31"
          ],
          "conclusion": "-A30",
          "natural": "It is not the case that the statistical results were manipulated."
        },
        {
          "step_number": 2,
          "rule_applied": "MT",
          "premises_used": [
            "(-(-A28 -> A29) -> A30)",
            "-A30"
          ],
          "conclusion": "(-A28 -> A29)",
          "natural": "If the research methodology is not transparent, then the raw data is accessible."
        },
        {
          "step_number": 3,
          "rule_applied": "MT",
          "premises_used": [
            "(-A28 -> A29)",
            "-A29"
          ],
          "conclusion": "A28",
          "natural": "The research methodology is transparent."
        },
        {
          "step_number": 4,
          "rule_applied": "MP",
          "premises_used": [
            "(A28 -> -A27)",
            "A28"
          ],
          "conclusion": "-A27",
          "natural": "It does not hold that the research data is fraudulent."
        },
        {
          "step_number": 5,
          "rule_applied": "MT",
          "premises_used": [
            "(-(A25 -> A23) -> A27)",
            "-A27"
          ],
          "conclusion": "(A25 -> A23)",
          "natural": "If the research budget is adequate, then the data validation is thorough."
        },
        {
          "step_number": 6,
          "rule_applied": "CD",
          "premises_used": [
            "(A25 -> A23)",
            "(A26 -> A24)",
            "(A25 | A26)"
          ],
          "conclusion": "(A23 | A24)",
          "natural": "Either the data validation is thorough or the expert review is independent."
        },
        {
          "step_number": 7,
          "rule_applied": "DE",
          "premises_used": [
            "(A23 | A24)",
            "(A23 -> (A13 -> (A10 -> A11)))",
            "(A24 -> (A13 -> (A10 -> A11)))"
          ],
          "conclusion": "(A13 -> (A10 -> A11))",
          "natural": "Assuming that the patient data is reliable, then if the clinical results are positive, the drug treatment is effective."
        },
        {
          "step_number": 8,
          "rule_applied": "DE",
          "premises_used": [
            "(A12 | A13)",
            "(A12 -> (A10 -> A11))",
            "(A13 -> (A10 -> A11))"
          ],
          "conclusion": "(A10 -> A11)",
          "natural": "If the clinical results are positive, then the drug treatment is effective."
        },
        {
          "step_number": 9,
          "rule_applied": "HS",
          "premises_used": [
            "(A10 -> A11)",
            "(A11 -> G)"
          ],
          "conclusion": "(A10 -> G)",
          "natural": "Provided that the clinical results are positive, the pharmaceutical company becomes profitable."
        },
        {
          "step_number": 10,
          "rule_applied": "DE",
          "premises_used": [
            "(A9 | A10)",
            "(A9 -> G)",
            "(A10 -> G)"
          ],
          "conclusion": "G",
          "natural": "The pharmaceutical company is profitable."
        }
      ]
    }
  ],
  "translations": {
    "domain_theme": "Pharmaceutical Research and Media",
    "atomic_facts": {
      "A1": "discontinued(clinical_trial)",
      "A2": "approved(drug)",
      "A3": "published(journal_article)",
      "A4": "rejected(journal_article)",
      "A5": "conflicts_with(funding_source, ethics_committee)",
      "A6": "compliant(funding_source, regulations)",
      "A7": "valid(informed_consent)",
      "A8": "proper(patient_screening)",
      "A9": "successful(pilot_study)",
      "A10": "positive(clinical_results)",
      "A11": "effective(drug_treatment)",
      "A12": "robust(statistical_analysis)",
      "A13": "reliable(patient_data)",
      "A14": "biased(sample_selection)",
      "A15": "dangerous(side_effects)",
      "A16": "identified(safety_issues)",
      "A17": "completed(phase_3_trial)",
      "A18": "accelerated(fda_review)",
      "A19": "launched(marketing_campaign)",
      "A20": "increased(market_share)",
      "A21": "positive(public_perception)",
      "A22": "negative(media_coverage)",
      "A23": "thorough(data_validation)",
      "A24": "independent(expert_review)",
      "A25": "adequate(research_budget)",
      "A26": "private(industry_funding)",
      "A27": "fraudulent(research_data)",
      "A28": "transparent(research_methodology)",
      "A29": "accessible(raw_data)",
      "A30": "manipulated(statistical_results)",
      "A31": "credible(peer_review)",
      "G": "profitable(pharmaceutical_company)"
    },
    "natural_facts": {
      "A1": "The clinical trial was discontinued.",
      "A2": "The drug was approved.",
      "A3": "The journal article was published.",
      "A4": "The journal article was rejected.",
      "A5": "The funding source conflicts with the ethics committee.",
      "A6": "The funding source is compliant with regulations.",
      "A7": "The informed consent is valid.",
      "A8": "The patient screening is proper.",
      "A9": "The pilot study was successful.",
      "A10": "The clinical results are positive.",
      "A11": "The drug treatment is effective.",
      "A12": "The statistical analysis is robust.",
      "A13": "The patient data is reliable.",
      "A14": "The sample selection is biased.",
      "A15": "The side effects are dangerous.",
      "A16": "Safety issues were identified.",
      "A17": "The phase 3 trial was completed.",
      "A18": "The FDA review was accelerated.",
      "A19": "The marketing campaign was launched.",
      "A20": "The market share increased.",
      "A21": "The public perception is positive.",
      "A22": "The media coverage is negative.",
      "A23": "The data validation is thorough.",
      "A24": "The expert review is independent.",
      "A25": "The research budget is adequate.",
      "A26": "The industry funding is private.",
      "A27": "The research data is fraudulent.",
      "A28": "The research methodology is transparent.",
      "A29": "The raw data is accessible.",
      "A30": "The statistical results were manipulated.",
      "A31": "The peer review is credible."
    },
    "prover9_expressions": [
      "(positive(clinical_results) -> effective(drug_treatment))",
      "(positive(clinical_results) -> profitable(pharmaceutical_company))",
      "(effective(drug_treatment) -> profitable(pharmaceutical_company))",
      "(robust(statistical_analysis) -> (positive(clinical_results) -> effective(drug_treatment)))",
      "(robust(statistical_analysis) | reliable(patient_data))",
      "(reliable(patient_data) -> (positive(clinical_results) -> effective(drug_treatment)))",
      "(biased(sample_selection) | (reliable(patient_data) -> (positive(clinical_results) -> effective(drug_treatment))))",
      "(identified(safety_issues) -> dangerous(side_effects))",
      "(completed(phase_3_trial) -> (identified(safety_issues) -> dangerous(side_effects)))",
      "(completed(phase_3_trial) | accelerated(fda_review))",
      "(accelerated(fda_review) -> (identified(safety_issues) -> dangerous(side_effects)))",
      "(launched(marketing_campaign) -> (completed(phase_3_trial) | accelerated(fda_review)))",
      "(launched(marketing_campaign) -> increased(market_share))",
      "(launched(marketing_campaign) -> positive(public_perception))",
      "(approved(drug) | -discontinued(clinical_trial))",
      "(increased(market_share) -> (completed(phase_3_trial) | accelerated(fda_review)))",
      "(positive(public_perception) -> increased(market_share))",
      "(negative(media_coverage) | (launched(marketing_campaign) -> positive(public_perception)))",
      "(thorough(data_validation) -> (reliable(patient_data) -> (positive(clinical_results) -> effective(drug_treatment))))",
      "(thorough(data_validation) | independent(expert_review))",
      "(independent(expert_review) -> (reliable(patient_data) -> (positive(clinical_results) -> effective(drug_treatment))))",
      "(adequate(research_budget) -> thorough(data_validation))",
      "(adequate(research_budget) | private(industry_funding))",
      "(private(industry_funding) -> independent(expert_review))",
      "(transparent(research_methodology) -> -fraudulent(research_data))",
      "(published(journal_article) -> approved(drug))",
      "(published(journal_article) | rejected(journal_article))",
      "(credible(peer_review) -> -manipulated(statistical_results))",
      "(rejected(journal_article) -> -discontinued(clinical_trial))",
      "(conflicts_with(funding_source, ethics_committee) -> compliant(funding_source, regulations))",
      "(conflicts_with(funding_source, ethics_committee) -> -compliant(funding_source, regulations))",
      "(conflicts_with(funding_source, ethics_committee) | (published(journal_article) | rejected(journal_article)))",
      "(proper(patient_screening) | -valid(informed_consent))",
      "(successful(pilot_study) -> profitable(pharmaceutical_company))",
      "(successful(pilot_study) | positive(clinical_results))",
      "(-(adequate(research_budget) -> thorough(data_validation)) -> fraudulent(research_data))",
      "(-(conflicts_with(funding_source, ethics_committee) -> compliant(funding_source, regulations)) -> valid(informed_consent))",
      "(-(-transparent(research_methodology) -> accessible(raw_data)) -> manipulated(statistical_results))",
      "(-transparent(research_methodology) -> accessible(raw_data))",
      "(-profitable(pharmaceutical_company) -> discontinued(clinical_trial))",
      "(-profitable(pharmaceutical_company) -> dangerous(side_effects))",
      "(-profitable(pharmaceutical_company) -> identified(safety_issues))",
      "(-profitable(pharmaceutical_company) -> -dangerous(side_effects))",
      "launched(marketing_campaign)",
      "transparent(research_methodology)",
      "credible(peer_review)",
      "profitable(pharmaceutical_company)",
      "-discontinued(clinical_trial)",
      "-biased(sample_selection)",
      "-approved(drug)",
      "-negative(media_coverage)",
      "-fraudulent(research_data)",
      "-accessible(raw_data)",
      "-manipulated(statistical_results)",
      "-conflicts_with(funding_source, ethics_committee)",
      "-valid(informed_consent)",
      "-proper(patient_screening)"
    ],
    "natural_expressions": [
      "If the clinical results are positive, then the drug treatment is effective.",
      "Provided that the clinical results are positive, the pharmaceutical company becomes profitable.",
      "Under the condition that the drug treatment is effective, the pharmaceutical company is profitable.",
      "Whenever the statistical analysis is robust, then if the clinical results are positive, the drug treatment is effective.",
      "Either the statistical analysis is robust or the patient data is reliable.",
      "Assuming that the patient data is reliable, then if the clinical results are positive, the drug treatment is effective.",
      "Either the sample selection is biased, or if the patient data is reliable, then positive clinical results lead to effective drug treatment.",
      "If safety issues are identified, then the side effects are dangerous.",
      "In the event that the phase 3 trial is completed, then if safety issues are identified, the side effects are dangerous.",
      "Either the phase 3 trial was completed or the FDA review was accelerated.",
      "Whenever the FDA review is accelerated, then if safety issues are identified, the side effects are dangerous.",
      "Under the condition that the marketing campaign is launched, either the phase 3 trial was completed or the FDA review was accelerated.",
      "If the marketing campaign is launched, then the market share increases.",
      "Provided that the marketing campaign is launched, the public perception is positive.",
      "Either the drug is approved or it is not the case that the clinical trial was discontinued.",
      "Whenever the market share increases, either the phase 3 trial was completed or the FDA review was accelerated.",
      "If the public perception is positive, then the market share increases.",
      "Either the media coverage is negative, or if the marketing campaign is launched, the public perception is positive.",
      "Assuming that the data validation is thorough, then if the patient data is reliable, then positive clinical results lead to effective drug treatment.",
      "Either the data validation is thorough or the expert review is independent.",
      "Under the condition that the expert review is independent, then if the patient data is reliable, then positive clinical results imply effective drug treatment.",
      "If the research budget is adequate, then the data validation is thorough.",
      "Either the research budget is adequate or the industry funding is private.",
      "Provided that the industry funding is private, the expert review is independent.",
      "If the research methodology is transparent, then it is not the case that the research data is fraudulent.",
      "Whenever the journal article is published, the drug is approved.",
      "Either the journal article is published or the journal article is rejected.",
      "In the event that the peer review is credible, it is not the case that the statistical results were manipulated.",
      "If the journal article is rejected, then it is not the case that the clinical trial was discontinued.",
      "Under the condition that the funding source conflicts with the ethics committee, the funding source is compliant with regulations.",
      "Assuming that the funding source conflicts with the ethics committee, it does not hold that the funding source is compliant with regulations.",
      "Either the funding source conflicts with the ethics committee, or either the journal article is published or the journal article is rejected.",
      "Either the patient screening is proper or the informed consent is not valid.",
      "If the pilot study is successful, then the pharmaceutical company is profitable.",
      "Either the pilot study is successful or the clinical results are positive.",
      "If it is not the case that if the research budget is adequate then the data validation is thorough, then the research data is fraudulent.",
      "If it does not hold that if the funding source conflicts with the ethics committee then the funding source is compliant with regulations, then the informed consent is valid.",
      "If it is not the case that if the research methodology is not transparent then the raw data is accessible, then the statistical results were manipulated.",
      "If the research methodology is not transparent, then the raw data is accessible.",
      "In the event that the pharmaceutical company is not profitable, the clinical trial was discontinued.",
      "Provided that the pharmaceutical company is not profitable, the side effects are dangerous.",
      "Under the condition that the pharmaceutical company is not profitable, safety issues were identified.",
      "Whenever the pharmaceutical company is not profitable, it does not hold that the side effects are dangerous.",
      "The marketing campaign was launched.",
      "The research methodology is transparent.",
      "The peer review is credible.",
      "The pharmaceutical company is profitable.",
      "It is not the case that the clinical trial was discontinued.",
      "The sample selection is not biased.",
      "The drug is not approved.",
      "The media coverage is not negative.",
      "It does not hold that the research data is fraudulent.",
      "The raw data is not accessible.",
      "It is not the case that the statistical results were manipulated.",
      "The funding source does not conflict with the ethics committee.",
      "The informed consent is not valid.",
      "The patient screening is not proper."
    ],
    "node_mappings": {
      "(A10 → A11)": {
        "formal": "(A10 → A11)",
        "prover9": "(A10 -> A11)",
        "prover9_expression": "(positive(clinical_results) -> effective(drug_treatment))",
        "natural": "If the clinical results are positive, then the drug treatment is effective."
      },
      "(A10 → G)": {
        "formal": "(A10 → G)",
        "prover9": "(A10 -> G)",
        "prover9_expression": "(positive(clinical_results) -> profitable(pharmaceutical_company))",
        "natural": "Provided that the clinical results are positive, the pharmaceutical company becomes profitable."
      },
      "(A11 → G)": {
        "formal": "(A11 → G)",
        "prover9": "(A11 -> G)",
        "prover9_expression": "(effective(drug_treatment) -> profitable(pharmaceutical_company))",
        "natural": "Under the condition that the drug treatment is effective, the pharmaceutical company is profitable."
      },
      "(A12 → (A10 → A11))": {
        "formal": "(A12 → (A10 → A11))",
        "prover9": "(A12 -> (A10 -> A11))",
        "prover9_expression": "(robust(statistical_analysis) -> (positive(clinical_results) -> effective(drug_treatment)))",
        "natural": "Whenever the statistical analysis is robust, then if the clinical results are positive, the drug treatment is effective."
      },
      "(A12 ∨ A13)": {
        "formal": "(A12 ∨ A13)",
        "prover9": "(A12 | A13)",
        "prover9_expression": "(robust(statistical_analysis) | reliable(patient_data))",
        "natural": "Either the statistical analysis is robust or the patient data is reliable."
      },
      "(A13 → (A10 → A11))": {
        "formal": "(A13 → (A10 → A11))",
        "prover9": "(A13 -> (A10 -> A11))",
        "prover9_expression": "(reliable(patient_data) -> (positive(clinical_results) -> effective(drug_treatment)))",
        "natural": "Assuming that the patient data is reliable, then if the clinical results are positive, the drug treatment is effective."
      },
      "(A14 ∨ (A13 → (A10 → A11)))": {
        "formal": "(A14 ∨ (A13 → (A10 → A11)))",
        "prover9": "(A14 | (A13 -> (A10 -> A11)))",
        "prover9_expression": "(biased(sample_selection) | (reliable(patient_data) -> (positive(clinical_results) -> effective(drug_treatment))))",
        "natural": "Either the sample selection is biased, or if the patient data is reliable, then positive clinical results lead to effective drug treatment."
      },
      "(A16 → A15)": {
        "formal": "(A16 → A15)",
        "prover9": "(A16 -> A15)",
        "prover9_expression": "(identified(safety_issues) -> dangerous(side_effects))",
        "natural": "If safety issues are identified, then the side effects are dangerous."
      },
      "(A17 → (A16 → A15))": {
        "formal": "(A17 → (A16 → A15))",
        "prover9": "(A17 -> (A16 -> A15))",
        "prover9_expression": "(completed(phase_3_trial) -> (identified(safety_issues) -> dangerous(side_effects)))",
        "natural": "In the event that the phase 3 trial is completed, then if safety issues are identified, the side effects are dangerous."
      },
      "(A17 ∨ A18)": {
        "formal": "(A17 ∨ A18)",
        "prover9": "(A17 | A18)",
        "prover9_expression": "(completed(phase_3_trial) | accelerated(fda_review))",
        "natural": "Either the phase 3 trial was completed or the FDA review was accelerated."
      },
      "(A18 → (A16 → A15))": {
        "formal": "(A18 → (A16 → A15))",
        "prover9": "(A18 -> (A16 -> A15))",
        "prover9_expression": "(accelerated(fda_review) -> (identified(safety_issues) -> dangerous(side_effects)))",
        "natural": "Whenever the FDA review is accelerated, then if safety issues are identified, the side effects are dangerous."
      },
      "(A19 → (A17 ∨ A18))": {
        "formal": "(A19 → (A17 ∨ A18))",
        "prover9": "(A19 -> (A17 | A18))",
        "prover9_expression": "(launched(marketing_campaign) -> (completed(phase_3_trial) | accelerated(fda_review)))",
        "natural": "Under the condition that the marketing campaign is launched, either the phase 3 trial was completed or the FDA review was accelerated."
      },
      "(A19 → A20)": {
        "formal": "(A19 → A20)",
        "prover9": "(A19 -> A20)",
        "prover9_expression": "(launched(marketing_campaign) -> increased(market_share))",
        "natural": "If the marketing campaign is launched, then the market share increases."
      },
      "(A19 → A21)": {
        "formal": "(A19 → A21)",
        "prover9": "(A19 -> A21)",
        "prover9_expression": "(launched(marketing_campaign) -> positive(public_perception))",
        "natural": "Provided that the marketing campaign is launched, the public perception is positive."
      },
      "(A2 ∨ ¬A1)": {
        "formal": "(A2 ∨ ¬A1)",
        "prover9": "(A2 | -A1)",
        "prover9_expression": "(approved(drug) | -discontinued(clinical_trial))",
        "natural": "Either the drug is approved or it is not the case that the clinical trial was discontinued."
      },
      "(A20 → (A17 ∨ A18))": {
        "formal": "(A20 → (A17 ∨ A18))",
        "prover9": "(A20 -> (A17 | A18))",
        "prover9_expression": "(increased(market_share) -> (completed(phase_3_trial) | accelerated(fda_review)))",
        "natural": "Whenever the market share increases, either the phase 3 trial was completed or the FDA review was accelerated."
      },
      "(A21 → A20)": {
        "formal": "(A21 → A20)",
        "prover9": "(A21 -> A20)",
        "prover9_expression": "(positive(public_perception) -> increased(market_share))",
        "natural": "If the public perception is positive, then the market share increases."
      },
      "(A22 ∨ (A19 → A21))": {
        "formal": "(A22 ∨ (A19 → A21))",
        "prover9": "(A22 | (A19 -> A21))",
        "prover9_expression": "(negative(media_coverage) | (launched(marketing_campaign) -> positive(public_perception)))",
        "natural": "Either the media coverage is negative, or if the marketing campaign is launched, the public perception is positive."
      },
      "(A23 → (A13 → (A10 → A11)))": {
        "formal": "(A23 → (A13 → (A10 → A11)))",
        "prover9": "(A23 -> (A13 -> (A10 -> A11)))",
        "prover9_expression": "(thorough(data_validation) -> (reliable(patient_data) -> (positive(clinical_results) -> effective(drug_treatment))))",
        "natural": "Assuming that the data validation is thorough, then if the patient data is reliable, then positive clinical results lead to effective drug treatment."
      },
      "(A23 ∨ A24)": {
        "formal": "(A23 ∨ A24)",
        "prover9": "(A23 | A24)",
        "prover9_expression": "(thorough(data_validation) | independent(expert_review))",
        "natural": "Either the data validation is thorough or the expert review is independent."
      },
      "(A24 → (A13 → (A10 → A11)))": {
        "formal": "(A24 → (A13 → (A10 → A11)))",
        "prover9": "(A24 -> (A13 -> (A10 -> A11)))",
        "prover9_expression": "(independent(expert_review) -> (reliable(patient_data) -> (positive(clinical_results) -> effective(drug_treatment))))",
        "natural": "Under the condition that the expert review is independent, then if the patient data is reliable, then positive clinical results imply effective drug treatment."
      },
      "(A25 → A23)": {
        "formal": "(A25 → A23)",
        "prover9": "(A25 -> A23)",
        "prover9_expression": "(adequate(research_budget) -> thorough(data_validation))",
        "natural": "If the research budget is adequate, then the data validation is thorough."
      },
      "(A25 ∨ A26)": {
        "formal": "(A25 ∨ A26)",
        "prover9": "(A25 | A26)",
        "prover9_expression": "(adequate(research_budget) | private(industry_funding))",
        "natural": "Either the research budget is adequate or the industry funding is private."
      },
      "(A26 → A24)": {
        "formal": "(A26 → A24)",
        "prover9": "(A26 -> A24)",
        "prover9_expression": "(private(industry_funding) -> independent(expert_review))",
        "natural": "Provided that the industry funding is private, the expert review is independent."
      },
      "(A28 → ¬A27)": {
        "formal": "(A28 → ¬A27)",
        "prover9": "(A28 -> -A27)",
        "prover9_expression": "(transparent(research_methodology) -> -fraudulent(research_data))",
        "natural": "If the research methodology is transparent, then it is not the case that the research data is fraudulent."
      },
      "(A3 → A2)": {
        "formal": "(A3 → A2)",
        "prover9": "(A3 -> A2)",
        "prover9_expression": "(published(journal_article) -> approved(drug))",
        "natural": "Whenever the journal article is published, the drug is approved."
      },
      "(A3 ∨ A4)": {
        "formal": "(A3 ∨ A4)",
        "prover9": "(A3 | A4)",
        "prover9_expression": "(published(journal_article) | rejected(journal_article))",
        "natural": "Either the journal article is published or the journal article is rejected."
      },
      "(A31 → ¬A30)": {
        "formal": "(A31 → ¬A30)",
        "prover9": "(A31 -> -A30)",
        "prover9_expression": "(credible(peer_review) -> -manipulated(statistical_results))",
        "natural": "In the event that the peer review is credible, it is not the case that the statistical results were manipulated."
      },
      "(A4 → ¬A1)": {
        "formal": "(A4 → ¬A1)",
        "prover9": "(A4 -> -A1)",
        "prover9_expression": "(rejected(journal_article) -> -discontinued(clinical_trial))",
        "natural": "If the journal article is rejected, then it is not the case that the clinical trial was discontinued."
      },
      "(A5 → A6)": {
        "formal": "(A5 → A6)",
        "prover9": "(A5 -> A6)",
        "prover9_expression": "(conflicts_with(funding_source, ethics_committee) -> compliant(funding_source, regulations))",
        "natural": "Under the condition that the funding source conflicts with the ethics committee, the funding source is compliant with regulations."
      },
      "(A5 → ¬A6)": {
        "formal": "(A5 → ¬A6)",
        "prover9": "(A5 -> -A6)",
        "prover9_expression": "(conflicts_with(funding_source, ethics_committee) -> -compliant(funding_source, regulations))",
        "natural": "Assuming that the funding source conflicts with the ethics committee, it does not hold that the funding source is compliant with regulations."
      },
      "(A5 ∨ (A3 ∨ A4))": {
        "formal": "(A5 ∨ (A3 ∨ A4))",
        "prover9": "(A5 | (A3 | A4))",
        "prover9_expression": "(conflicts_with(funding_source, ethics_committee) | (published(journal_article) | rejected(journal_article)))",
        "natural": "Either the funding source conflicts with the ethics committee, or either the journal article is published or the journal article is rejected."
      },
      "(A8 ∨ ¬A7)": {
        "formal": "(A8 ∨ ¬A7)",
        "prover9": "(A8 | -A7)",
        "prover9_expression": "(proper(patient_screening) | -valid(informed_consent))",
        "natural": "Either the patient screening is proper or the informed consent is not valid."
      },
      "(A9 → G)": {
        "formal": "(A9 → G)",
        "prover9": "(A9 -> G)",
        "prover9_expression": "(successful(pilot_study) -> profitable(pharmaceutical_company))",
        "natural": "If the pilot study is successful, then the pharmaceutical company is profitable."
      },
      "(A9 ∨ A10)": {
        "formal": "(A9 ∨ A10)",
        "prover9": "(A9 | A10)",
        "prover9_expression": "(successful(pilot_study) | positive(clinical_results))",
        "natural": "Either the pilot study is successful or the clinical results are positive."
      },
      "(¬(A25 → A23) → A27)": {
        "formal": "(¬(A25 → A23) → A27)",
        "prover9": "(-(A25 -> A23) -> A27)",
        "prover9_expression": "(-(adequate(research_budget) -> thorough(data_validation)) -> fraudulent(research_data))",
        "natural": "If it is not the case that if the research budget is adequate then the data validation is thorough, then the research data is fraudulent."
      },
      "(¬(A5 → A6) → A7)": {
        "formal": "(¬(A5 → A6) → A7)",
        "prover9": "(-(A5 -> A6) -> A7)",
        "prover9_expression": "(-(conflicts_with(funding_source, ethics_committee) -> compliant(funding_source, regulations)) -> valid(informed_consent))",
        "natural": "If it does not hold that if the funding source conflicts with the ethics committee then the funding source is compliant with regulations, then the informed consent is valid."
      },
      "(¬(¬A28 → A29) → A30)": {
        "formal": "(¬(¬A28 → A29) → A30)",
        "prover9": "(-(-A28 -> A29) -> A30)",
        "prover9_expression": "(-(-transparent(research_methodology) -> accessible(raw_data)) -> manipulated(statistical_results))",
        "natural": "If it is not the case that if the research methodology is not transparent then the raw data is accessible, then the statistical results were manipulated."
      },
      "(¬A28 → A29)": {
        "formal": "(¬A28 → A29)",
        "prover9": "(-A28 -> A29)",
        "prover9_expression": "(-transparent(research_methodology) -> accessible(raw_data))",
        "natural": "If the research methodology is not transparent, then the raw data is accessible."
      },
      "(¬G → A1)": {
        "formal": "(¬G → A1)",
        "prover9": "(-G -> A1)",
        "prover9_expression": "(-profitable(pharmaceutical_company) -> discontinued(clinical_trial))",
        "natural": "In the event that the pharmaceutical company is not profitable, the clinical trial was discontinued."
      },
      "(¬G → A15)": {
        "formal": "(¬G → A15)",
        "prover9": "(-G -> A15)",
        "prover9_expression": "(-profitable(pharmaceutical_company) -> dangerous(side_effects))",
        "natural": "Provided that the pharmaceutical company is not profitable, the side effects are dangerous."
      },
      "(¬G → A16)": {
        "formal": "(¬G → A16)",
        "prover9": "(-G -> A16)",
        "prover9_expression": "(-profitable(pharmaceutical_company) -> identified(safety_issues))",
        "natural": "Under the condition that the pharmaceutical company is not profitable, safety issues were identified."
      },
      "(¬G → ¬A15)": {
        "formal": "(¬G → ¬A15)",
        "prover9": "(-G -> -A15)",
        "prover9_expression": "(-profitable(pharmaceutical_company) -> -dangerous(side_effects))",
        "natural": "Whenever the pharmaceutical company is not profitable, it does not hold that the side effects are dangerous."
      },
      "A19": {
        "formal": "A19",
        "prover9": "A19",
        "prover9_expression": "launched(marketing_campaign)",
        "natural": "The marketing campaign was launched."
      },
      "A28": {
        "formal": "A28",
        "prover9": "A28",
        "prover9_expression": "transparent(research_methodology)",
        "natural": "The research methodology is transparent."
      },
      "A31": {
        "formal": "A31",
        "prover9": "A31",
        "prover9_expression": "credible(peer_review)",
        "natural": "The peer review is credible."
      },
      "G": {
        "formal": "G",
        "prover9": "G",
        "prover9_expression": "profitable(pharmaceutical_company)",
        "natural": "The pharmaceutical company is profitable."
      },
      "¬A1": {
        "formal": "¬A1",
        "prover9": "-A1",
        "prover9_expression": "-discontinued(clinical_trial)",
        "natural": "It is not the case that the clinical trial was discontinued."
      },
      "¬A14": {
        "formal": "¬A14",
        "prover9": "-A14",
        "prover9_expression": "-biased(sample_selection)",
        "natural": "The sample selection is not biased."
      },
      "¬A2": {
        "formal": "¬A2",
        "prover9": "-A2",
        "prover9_expression": "-approved(drug)",
        "natural": "The drug is not approved."
      },
      "¬A22": {
        "formal": "¬A22",
        "prover9": "-A22",
        "prover9_expression": "-negative(media_coverage)",
        "natural": "The media coverage is not negative."
      },
      "¬A27": {
        "formal": "¬A27",
        "prover9": "-A27",
        "prover9_expression": "-fraudulent(research_data)",
        "natural": "It does not hold that the research data is fraudulent."
      },
      "¬A29": {
        "formal": "¬A29",
        "prover9": "-A29",
        "prover9_expression": "-accessible(raw_data)",
        "natural": "The raw data is not accessible."
      },
      "¬A30": {
        "formal": "¬A30",
        "prover9": "-A30",
        "prover9_expression": "-manipulated(statistical_results)",
        "natural": "It is not the case that the statistical results were manipulated."
      },
      "¬A5": {
        "formal": "¬A5",
        "prover9": "-A5",
        "prover9_expression": "-conflicts_with(funding_source, ethics_committee)",
        "natural": "The funding source does not conflict with the ethics committee."
      },
      "¬A7": {
        "formal": "¬A7",
        "prover9": "-A7",
        "prover9_expression": "-valid(informed_consent)",
        "natural": "The informed consent is not valid."
      },
      "¬A8": {
        "formal": "¬A8",
        "prover9": "-A8",
        "prover9_expression": "-proper(patient_screening)",
        "natural": "The patient screening is not proper."
      }
    }
  }
}